Insmed Incorporated (NASDAQ:INSM) Shares Bought by Values First Advisors Inc.

Values First Advisors Inc. raised its holdings in Insmed Incorporated (NASDAQ:INSM) by 4.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,199 shares of the biopharmaceutical company’s stock after buying an additional 221 shares during the period. Values First Advisors Inc.’s holdings in Insmed were worth $359,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Jennison Associates LLC boosted its holdings in Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC acquired a new stake in Insmed in the 4th quarter valued at about $586,000. Orion Portfolio Solutions LLC boosted its stake in shares of Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after buying an additional 9,170 shares during the period. Ally Bridge Group NY LLC grew its position in shares of Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after buying an additional 21,833 shares in the last quarter. Finally, Vestal Point Capital LP increased its stake in shares of Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after buying an additional 850,000 shares during the period.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent research reports. Stifel Nicolaus lifted their price target on shares of Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday. Guggenheim lifted their price objective on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Finally, Truist Financial reaffirmed a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $85.60.

Insmed Trading Down 0.4 %

NASDAQ:INSM opened at $79.60 on Thursday. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $82.04. The stock’s 50 day moving average price is $73.15 and its 200 day moving average price is $73.16. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 2,978 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.36, for a total value of $188,686.08. Following the completion of the sale, the chief executive officer now directly owns 392,589 shares of the company’s stock, valued at approximately $24,874,439.04. This represents a 0.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 3,470 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total value of $227,979.00. Following the transaction, the chief financial officer now directly owns 114,736 shares in the company, valued at approximately $7,538,155.20. This represents a 2.94 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 481,833 shares of company stock worth $37,345,553. Insiders own 4.60% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.